Table 1

MKC-3946 combination indices (CI) with bortezomib or 17-AAG

Bortezomib, nMMKC-3946, μMCI17-AAG, nMMKC-3946, μMCI
RPMI 8226       
 1.04 125 1.06 
 10 0.99 125 10 1.02 
 0.91 250 0.89 
 10 0.86 250 10 0.73 
INA6       
 2.5 1.14 31.3 1.04 
 2.5 10 1.04 31.3 10 0.75 
 1.06 62.5 0.76 
 10 0.96 62.5 10 0.44 
Bortezomib, nMMKC-3946, μMCI17-AAG, nMMKC-3946, μMCI
RPMI 8226       
 1.04 125 1.06 
 10 0.99 125 10 1.02 
 0.91 250 0.89 
 10 0.86 250 10 0.73 
INA6       
 2.5 1.14 31.3 1.04 
 2.5 10 1.04 31.3 10 0.75 
 1.06 62.5 0.76 
 10 0.96 62.5 10 0.44 

RPMI 8226 and INA6 cells were treated with bortezomib or 17-AAG and/or MKC-3946. Cytotoxicity was assessed by [3H]-thymidine uptake. CI was calculated using CompuSyn software. CI < 0.9 indicates synergistic effects, and CI > 0.9 indicates additive effects.

Close Modal

or Create an Account

Close Modal
Close Modal